Administration of Chlorpromazine as a Treatment for COVID-19
Status:
Not yet recruiting
Trial end date:
2020-11-01
Target enrollment:
Participant gender:
Summary
In this study, defined cases of COVID-19 confirmed with PCR, with a mild, moderate or severe
pneumonia will be treated with chlorpromazine. The improvement in clinical & laboratory
manifestations will be evaluated in treated patient compared to control group.